GSK-25

• UNSPSC Description:

  GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM). GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 μM for CYP2C9, CYP2D6, CYP3A4, respectively)[1].

• Target Antigen:

  Ribosomal S6 Kinase (RSK); ROCK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Cytoskeleton;MAPK/ERK Pathway;Stem Cell/Wnt;TGF-beta/Smad

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/gsk-25.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC(C2=NC(C3=C(F)C=C(Cl)C=C3)C(C(NC4=C(F)C=C(NN=C5)C5=C4)=O)=C(C)N2)=CC=N1

• Molecular Weight:

  513.33

• References & Citations:

  [1]Sehon CA, et al. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem. 2008 Nov 13;51(21):6631-4.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  874119-56-9